Armistice Capital, LLC Cellectis S.A. Transaction History

Armistice Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $8.12 Million - $13.5 Million	-800,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $1.05 Million - $1.48 Million	72,000 Added 9.89%	800,000 $12.5 Million
Q1 2019 May 15, 2019	BUY	$15.53 - $19.75 $2.16 Million - $2.75 Million	139,000 Added 23.6%	728,000 $13.4 Million
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $171,380 - $312,510	-11,000 Reduced 1.83%	589,000 $9.81 Million
Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $15.6 Million - $18.4 Million	600,000 New	600,000 $16.9 Million

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.